Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

Shares of Bristol Myers Squibb (BMY) fell more than 4% after the closing bell on Tuesday after the biopharma company reported ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...